At a Glance
| Indication | Primary photoreceptor diseases |
| Drug | lemiretprocel |
| Mechanism of Action | iPSC-derived cell therapy |
| Company | BlueRock Therapeutics LP |
| Trial Phase | Phase 1/2a |
| Trial Acronym | CLARICO |
| NCT ID | NCT06789445 |
| Category | Regulatory Milestone |
| Sub Category | Orphan Drug Designation |
| Therapeutic Area | Rare Diseases & Genetics |
| Regulatory Agency | U.S. FDA, EU EMA |
| Designation Type | Orphan Drug Designation, Fast Track designation |
| Approved Region | United States, European Union |
| Patient Population | Adults with primary photoreceptor disease |
| Trial Enrollment Size | Up to approximately 54 participants |
| Development Partner | Bayer AG |
BlueRock's Lemiretprocel Receives Orphan Drug Designations from FDA and EMA
BlueRock Therapeutics, a wholly owned subsidiary of Bayer AG, announced that its investigational cell therapy, lemiretprocel (OpCT-001), has received Orphan Drug Designations from both the U.S. FDA and the EU EMA. The FDA designations are for treating retinitis pigmentosa and cone-rod dystrophy. The EMA designations cover syndromic and non-syndromic inherited retinal disorders (IRDs) of both rod-dominant and cone-dominant phenotypes. Lemiretprocel is an induced pluripotent stem cell (iPSC)-derived cell therapy currently being tested in a Phase 1/2a clinical study (CLARICO) for primary photoreceptor diseases, including retinitis pigmentosa, Usher syndrome, and cone-rod dystrophies, with the goal of restoring vision by replacing lost retinal cells.
- Lemiretprocel (OpCT-001) has been granted Orphan Drug Designations by the U.S. FDA for retinitis pigmentosa and cone-rod dystrophy, and by the EU EMA for syndromic and non-syndromic inherited retinal disorders (IRDs) of rod-dominant and cone-dominant phenotypes. These designations are crucial for advancing therapies for rare diseases, offering incentives like market exclusivity and protocol assistance, and underscore the significant unmet medical need in these conditions.
- The investigational therapy, lemiretprocel, is an iPSC-derived cell therapy designed to restore vision by replacing lost photoreceptor cells in the retina. This innovative approach targets the underlying cause of primary photoreceptor diseases, such as retinitis pigmentosa, Usher syndrome, and cone-rod dystrophies, which currently have very limited treatment options, offering a potential paradigm shift in managing these debilitating conditions.
- Lemiretprocel is currently undergoing evaluation in the CLARICO study, a Phase 1/2a first-in-human, multisite interventional clinical trial. This study aims to assess the safety, tolerability, and clinical outcomes of OpCT-001 in up to approximately 54 adults with primary photoreceptor disease. The trial features a dose-escalation Phase 1 and a Phase 2 designed to gather additional safety data and evaluate measures of visual function, functional vision, and anatomic engraftment.
Frequently Asked Questions
Is there a cure for retinitis pigmentosa in 2026?
A universal cure for retinitis pigmentosa is not anticipated to be available by 2026. While significant advancements are being made in gene therapies, such as Luxturna for RPE65-mediated RP, and other modalities like optogenetics and stem cell therapies are in various stages of clinical development, these represent targeted treatments or investigational approaches rather than a broad cure for all forms of the genetically heterogeneous condition. Research continues to focus on slowing progression, restoring vision, and addressing specific genetic mutations.
What diseases affect photoreceptors?
Photoreceptors are primarily affected by inherited retinal dystrophies, including retinitis pigmentosa, Leber congenital amaurosis, and Stargardt disease, which lead to progressive degeneration. Acquired conditions such as age-related macular degeneration (AMD), particularly its dry form, directly impact photoreceptor integrity and function. Other significant causes include diabetic retinopathy, retinal detachments, and certain drug toxicities or inflammatory retinopathies.
Can the photoreceptors in eyes be repaired?
Mature mammalian photoreceptors generally do not spontaneously regenerate or repair themselves after significant damage or loss. However, therapeutic strategies are actively being developed and investigated. These include gene therapies aimed at preserving existing photoreceptors or improving their function, and cell-based therapies, such as the transplantation of induced pluripotent stem cell-derived photoreceptor precursors, to replace lost cells and restore visual function.
What is the only FDA-approved treatment for retinitis pigmentosa?
Luxturna (voretigene neparvovec) is the only FDA-approved gene therapy for retinitis pigmentosa. It is indicated for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy, a specific genetic form of the disease. This adeno-associated virus vector-based gene therapy is administered via subretinal injection to deliver a functional copy of the RPE65 gene.
Contact Us
📍
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
✉️
For General Inquiry
info@pienomial.com
